Endometrial Cancer at Recurrence: To Re-sequence or Not to Re-sequence

Overview

Journal Gynecol Oncol Rep

Publisher Elsevier

Date 2024 Jun 6

PMID 38841264

Authors

Katherine Fuh

Beryl L Manning-Geist

Affiliations

Soon will be listed here.

References

McMeekin D, Filiaci V, Thigpen J, Gallion H, Fleming G, Rodgers W . The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007; 106(1):16-22. DOI: 10.1016/j.ygyno.2007.04.032. View

Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Dal Cin E . Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Lung Cancer. 2019; 134:225-232. DOI: 10.1016/j.lungcan.2019.06.010. View

Davidson B, Foote J, Clark L, Broadwater G, Ehrisman J, Gehrig P . Tumor grade and chemotherapy response in endometrioid endometrial cancer. Gynecol Oncol Rep. 2016; 17:3-6. PMC: 4899082. DOI: 10.1016/j.gore.2016.04.006. View

Urick M, Bell D . Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019; 19(9):510-521. PMC: 7446243. DOI: 10.1038/s41568-019-0177-x. View

Berek J, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S . FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023; 34(5):e85. PMC: 10482588. DOI: 10.3802/jgo.2023.34.e85. View

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D . Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486(7404):532-6. PMC: 3927413. DOI: 10.1038/nature11156. View

Soumerai T, Donoghue M, Bandlamudi C, Srinivasan P, Chang M, Zamarin D . Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin Cancer Res. 2018; 24(23):5939-5947. PMC: 6279519. DOI: 10.1158/1078-0432.CCR-18-0412. View

Eskander R, Sill M, Beffa L, Moore R, Hope J, Musa F . Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023; 388(23):2159-2170. PMC: 10351614. DOI: 10.1056/NEJMoa2302312. View

Dessources K, Da Cruz Paula A, Pareja F, Stylianou A, Cybulska P, Farmanbar A . Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. JCO Precis Oncol. 2020; 4. PMC: 7608574. DOI: 10.1200/PO.20.00044. View

10.

Mota A, Oltra S, Selenica P, Moiola C, Casas-Arozamena C, Lopez-Gil C . Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. Oncogene. 2022; 41(13):1835-1850. PMC: 8956509. DOI: 10.1038/s41388-022-02221-0. View

11.

Ashley C, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N . Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol Oncol. 2018; 152(1):11-19. PMC: 6726428. DOI: 10.1016/j.ygyno.2018.10.032. View

12.

Stasenko M, Tunnage I, Ashley C, Rubinstein M, Latham A, Da Cruz Paula A . Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol. 2019; 156(1):194-202. PMC: 6980651. DOI: 10.1016/j.ygyno.2019.10.028. View

13.

Meric-Bernstam F, Makker V, Oaknin A, Oh D, Banerjee S, Gonzalez-Martin A . Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2023; 42(1):47-58. PMC: 10730032. DOI: 10.1200/JCO.23.02005. View

14.

Kurnit K, Kim G, Fellman B, Urbauer D, Mills G, Zhang W . CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017; 30(7):1032-1041. PMC: 5493522. DOI: 10.1038/modpathol.2017.15. View